Keywords: skyepharma, climbs, gsk, plans, paxil, cr, launch
SkyePharma climbs as GSK plans Paxil CR launch
Article | 01 April 2002
Shares in UK company SkyePharma climbed nearly 25% to 65.5 pence inafternoon trading on March 27, after the company announced that partner GlaxoSmithKline ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- US Supreme Court says patent settlement can "sometimes" be illegal
- Negative US patent ruling for Novo Nordisk on Prandin
- Daiichi Sankyo files for Japanese approval of Prasugrel
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
